Celsion
This article was originally published in The Gray Sheet
Executive Summary
Firm is gearing up to commence Phase I trials of its microwave treatment system for breast cancer following investigational device exemption clearance, announced Aug. 16. The trial will include ten patients to be treated at two sites. The device uses heat to destroy tumors in a "non toxic" manner, the firm explains (1"The Gray Sheet" Oct. 26, 1998, p. 19). Separately, Celsion is awaiting FDA sign-off to begin Phase II trials of its microwave benign prostatic hyperplasia treatment system. The company completed Phase I trials on ten patients earlier this year
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.